{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T04:46:19Z","timestamp":1760244379894,"version":"build-2065373602"},"reference-count":50,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T00:00:00Z","timestamp":1747699200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100019018","name":"Chinese Academy of Medical Sciences Initiative for Innovative Medicine","doi-asserted-by":"publisher","award":["2021-I2M-5-005"],"award-info":[{"award-number":["2021-I2M-5-005"]}],"id":[{"id":"10.13039\/501100019018","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy Oncology"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.omton.2025.200999","type":"journal-article","created":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T03:01:03Z","timestamp":1747969263000},"page":"200999","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["An attenuated coxsackievirus B5 mutant carrying VP1-N157K retains oncolytic potency against non-small cell lung cancer"],"prefix":"10.1016","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2323-0226","authenticated-orcid":false,"given":"Lifang","family":"Song","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bopei","family":"Cui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiushuang","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chaoying","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qian","family":"wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jialu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yajing","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guanxing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yulong","family":"Fu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kelei","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaotian","family":"Hao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fan","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xing","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qunying","family":"Mao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhenglun","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongxin","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.omton.2025.200999_bib1","doi-asserted-by":"crossref","first-page":"229","DOI":"10.5501\/wjv.v10.i5.229","article-title":"Oncolytic virus therapy in cancer: A current review","volume":"10","author":"Santos Apolonio","year":"2021","journal-title":"World J. Virol."},{"key":"10.1016\/j.omton.2025.200999_bib2","doi-asserted-by":"crossref","first-page":"159","DOI":"10.3390\/curroncol28010019","article-title":"Oncolytic Viruses and Hematological Malignancies: A New Class of Immunotherapy Drugs","volume":"28","author":"Innao","year":"2020","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.omton.2025.200999_bib3","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.ejphar.2018.08.042","article-title":"The advent of oncolytic virotherapy in oncology: The Rigvir\u00ae story","volume":"837","author":"Alberts","year":"2018","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.omton.2025.200999_bib4","doi-asserted-by":"crossref","first-page":"171","DOI":"10.2174\/1568009618666171129221503","article-title":"Oncorine, the World First Oncolytic Virus Medicine and its Update in China","volume":"18","author":"Liang","year":"2018","journal-title":"Curr. Cancer Drug Targets"},{"key":"10.1016\/j.omton.2025.200999_bib6","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s10014-022-00431-8","article-title":"Implications of immune cells in oncolytic herpes simplex virotherapy for glioma","volume":"39","author":"Otani","year":"2022","journal-title":"Brain Tumor Pathol."},{"key":"10.1016\/j.omton.2025.200999_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40257-016-0238-9","article-title":"Talimogene Laherparepvec (T-VEC) and Other Oncolytic Viruses for the Treatment of Melanoma","volume":"18","author":"Bommareddy","year":"2017","journal-title":"Am. J. Clin. Dermatol."},{"key":"10.1016\/j.omton.2025.200999_bib7","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1126\/science.274.5286.373","article-title":"An adenovirus mutant that replicates selectively in p53-deficient human tumor cells","volume":"274","author":"Bischoff","year":"1996","journal-title":"Science"},{"key":"10.1016\/j.omton.2025.200999_bib8","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1038\/gt.2009.97","article-title":"Efficient delivery of angiostatin K1-5 into tumors following insertion of an NGR peptide into adenovirus capsid","volume":"16","author":"Jullienne","year":"2009","journal-title":"Gene Ther."},{"key":"10.1016\/j.omton.2025.200999_bib9","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001647","article-title":"IL-21 arming potentiates the anti-tumor activity of an oncolytic vaccinia virus in monotherapy and combination therapy","volume":"9","author":"Chen","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.omton.2025.200999_bib10","first-page":"1471","article-title":"Oncolysis of vascular malignant human melanoma tumors by Coxsackievirus A21","volume":"26","author":"Au","year":"2005","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.omton.2025.200999_bib11","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1158\/1078-0432.CCR-0690-3","article-title":"Systemic therapy of malignant human melanoma tumors by a common cold-producing enterovirus, coxsackievirus a21","volume":"10","author":"Shafren","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omton.2025.200999_bib12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.omto.2018.02.001","article-title":"Oncolytic Immunotherapy for Bladder Cancer Using Coxsackie A21 Virus","volume":"9","author":"Annels","year":"2018","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.omton.2025.200999_bib13","doi-asserted-by":"crossref","first-page":"5818","DOI":"10.1158\/1078-0432.CCR-18-4022","article-title":"Phase I Trial of an ICAM-1-Targeted Immunotherapeutic-Coxsackievirus A21 (CVA21) as an Oncolytic Agent Against Non Muscle-Invasive Bladder Cancer","volume":"25","author":"Annels","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omton.2025.200999_bib14","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1111\/j.1365-2141.2007.06550.x","article-title":"Oncolytic Coxsackievirus A21 as a novel therapy for multiple myeloma","volume":"137","author":"Au","year":"2007","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.omton.2025.200999_bib15","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1002\/pros.20741","article-title":"Potent oncolytic activity of human enteroviruses against human prostate cancer","volume":"68","author":"Berry","year":"2008","journal-title":"Prostate"},{"key":"10.1016\/j.omton.2025.200999_bib16","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s10549-008-9899-2","article-title":"Systemic targeting of metastatic human breast tumor xenografts by Coxsackievirus A21","volume":"113","author":"Skelding","year":"2009","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.omton.2025.200999_bib17","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1158\/0008-5472.CAN-11-3185","article-title":"Coxsackievirus B3 is an oncolytic virus with immunostimulatory properties that is active against lung adenocarcinoma","volume":"72","author":"Miyamoto","year":"2012","journal-title":"Cancer Res."},{"key":"10.1016\/j.omton.2025.200999_bib18","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.omto.2019.07.003","article-title":"Coxsackievirus Type B3 Is a Potent Oncolytic Virus against KRAS-Mutant Lung Adenocarcinoma","volume":"14","author":"Deng","year":"2019","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.omton.2025.200999_bib19","doi-asserted-by":"crossref","first-page":"5210","DOI":"10.1002\/cam4.3143","article-title":"Novel recombinant coxsackievirus B3 with genetically inserted basic peptide elicits robust antitumor activity against lung cancer","volume":"9","author":"Cai","year":"2020","journal-title":"Cancer Med."},{"key":"10.1016\/j.omton.2025.200999_bib20","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1089\/hum.2018.036","article-title":"Heparan Sulfate Binding Coxsackievirus B3 Strain PD: A Novel Avirulent Oncolytic Agent Against Human Colorectal Carcinoma","volume":"29","author":"Hazini","year":"2018","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omton.2025.200999_bib21","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s12985-018-0975-x","article-title":"Oncolytic activity of a coxsackievirus B3 strain in human endometrial cancer cell lines","volume":"15","author":"Lin","year":"2018","journal-title":"Virol. J."},{"key":"10.1016\/j.omton.2025.200999_bib22","doi-asserted-by":"crossref","first-page":"81","DOI":"10.21873\/anticanres.14753","article-title":"Development of New Oncolytic Virotherapy Targeting Breast Cancer Using Coxsackievirus B3","volume":"41","author":"Sagara","year":"2021","journal-title":"Anticancer Res."},{"key":"10.1016\/j.omton.2025.200999_bib23","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1038\/s41392-023-01603-4","article-title":"Non-small cell lung cancers (NSCLCs) oncolysis using coxsackievirus B5 and synergistic DNA-damage response inhibitors","volume":"8","author":"Cui","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.omton.2025.200999_bib24","doi-asserted-by":"crossref","first-page":"629","DOI":"10.2217\/fmb.15.5","article-title":"Coxsackievirus B3 replication and pathogenesis","volume":"10","author":"Garmaroudi","year":"2015","journal-title":"Future Microbiol."},{"key":"10.1016\/j.omton.2025.200999_bib25","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.virol.2010.12.014","article-title":"Enterovirus infections of the central nervous system","volume":"411","author":"Rhoades","year":"2011","journal-title":"Virology"},{"key":"10.1016\/j.omton.2025.200999_bib26","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.tim.2012.03.009","article-title":"Viral disruption of the blood-brain barrier","volume":"20","author":"Spindler","year":"2012","journal-title":"Trends Microbiol."},{"key":"10.1016\/j.omton.2025.200999_bib27","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1038\/nm.1776","article-title":"Engineering microRNA responsiveness to decrease virus pathogenicity","volume":"14","author":"Kelly","year":"2008","journal-title":"Nat. Med."},{"key":"10.1016\/j.omton.2025.200999_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2022.215849","article-title":"A new miRNA-Modified coxsackievirus B3 inhibits triple negative breast cancer growth with improved safety profile in immunocompetent mice","volume":"548","author":"Bahreyni","year":"2022","journal-title":"Cancer Lett."},{"key":"10.1016\/j.omton.2025.200999_bib29","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1011662","article-title":"VP2 residue N142 of coxsackievirus A10 is critical for the interaction with KREMEN1 receptor and neutralizing antibodies and the pathogenicity in mice","volume":"19","author":"Li","year":"2023","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.omton.2025.200999_bib30","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/0264-410X(85)90124-0","article-title":"Development and characterization of cold-adapted viruses for use as live virus vaccines","volume":"3","author":"Maassab","year":"1985","journal-title":"Vaccine"},{"key":"10.1016\/j.omton.2025.200999_bib31","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.virs.2022.03.005","article-title":"Construction and verification of an infectious cDNA clone of coxsackievirus B5","volume":"37","author":"Song","year":"2022","journal-title":"Virol. Sin."},{"key":"10.1016\/j.omton.2025.200999_bib32","doi-asserted-by":"crossref","DOI":"10.3390\/v9070178","article-title":"Almond Skin Extracts Abrogate HSV-1 Replication by Blocking Virus Binding to the Cell","volume":"9","author":"Bisignano","year":"2017","journal-title":"Viruses"},{"key":"10.1016\/j.omton.2025.200999_bib33","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.jmii.2020.06.008","article-title":"Clinical characteristics of echovirus 11 and coxsackievirus B5 infections in Taiwanese children requiring hospitalization","volume":"54","author":"Chen","year":"2021","journal-title":"J. Microbiol. Immunol. Infect."},{"key":"10.1016\/j.omton.2025.200999_bib34","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1272\/jnms.JNMS.2018_85-28","article-title":"Coxsackievirus B5 Aseptic Meningitis in Infants in Chiba Prefecture, Japan, in 2016","volume":"85","author":"Tsuno","year":"2018","journal-title":"J. Nippon Med. Sch."},{"key":"10.1016\/j.omton.2025.200999_bib35","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1038\/sj.gt.3301885","article-title":"ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties","volume":"10","author":"Liu","year":"2003","journal-title":"Gene Ther."},{"key":"10.1016\/j.omton.2025.200999_bib36","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13061383","article-title":"Talimogene Laherparepvec (T-VEC): An Intralesional Cancer Immunotherapy for Advanced Melanoma","volume":"13","author":"Ferrucci","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.omton.2025.200999_bib37","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1002\/1873-3468.13647","article-title":"MiR-375-mediated suppression of engineered coxsackievirus B3 in pancreatic cells","volume":"594","author":"Pryshliak","year":"2020","journal-title":"FEBS Lett."},{"key":"10.1016\/j.omton.2025.200999_bib38","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1089\/hum.2020.228","article-title":"miR-375- and miR-1-Regulated Coxsackievirus B3 Has No Pancreas and Heart Toxicity But Strong Antitumor Efficiency in Colorectal Carcinomas","volume":"32","author":"Hazini","year":"2021","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omton.2025.200999_bib39","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1002\/jmv.20303","article-title":"Phenotypic and genetic changes in coxsackievirus B5 following repeated passage in mouse pancreas in vivo","volume":"75","author":"Al-Hello","year":"2005","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.omton.2025.200999_bib40","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1002\/jmv.21391","article-title":"Amino acids of Coxsackie B5 virus are critical for infection of the murine insulinoma cell line, MIN-6","volume":"81","author":"Al-Hello","year":"2009","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.omton.2025.200999_bib41","doi-asserted-by":"crossref","first-page":"6032","DOI":"10.1073\/pnas.90.13.6032","article-title":"Molecular and biological changes in the cold-adapted \u201cmaster strain\u201d A\/AA\/6\/60 (H2N2) influenza virus","volume":"90","author":"Herlocher","year":"1993","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omton.2025.200999_bib42","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01948-17","article-title":"Parainfluenza Virus Infection Sensitizes Cancer Cells to DNA-Damaging Agents: Implications for Oncolytic Virus Therapy","volume":"92","author":"Fox","year":"2018","journal-title":"J. Virol."},{"key":"10.1016\/j.omton.2025.200999_bib43","doi-asserted-by":"crossref","first-page":"12603","DOI":"10.1128\/JVI.78.22.12603-12612.2004","article-title":"Enhanced cellular receptor usage by a bioselected variant of coxsackievirus a21","volume":"78","author":"Johansson","year":"2004","journal-title":"J. Virol."},{"key":"10.1016\/j.omton.2025.200999_bib44","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1093\/infdis\/175.3.697","article-title":"Clinical coxsackievirus B isolates differ from laboratory strains in their interaction with two cell surface receptors","volume":"175","author":"Bergelson","year":"1997","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.omton.2025.200999_bib45","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/eurheartj\/16.suppl_O.15","article-title":"Genetics of coxsackievirus B3 cardiovirulence","volume":"16","author":"Tracy","year":"1995","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.omton.2025.200999_bib46","doi-asserted-by":"crossref","first-page":"7811","DOI":"10.1128\/jvi.70.11.7811-7818.1996","article-title":"A mutation in the puff region of VP2 attenuates the myocarditic phenotype of an infectious cDNA of the Woodruff variant of coxsackievirus B3","volume":"70","author":"Knowlton","year":"1996","journal-title":"J. Virol."},{"key":"10.1016\/j.omton.2025.200999_bib47","doi-asserted-by":"crossref","first-page":"13987","DOI":"10.1128\/JVI.78.24.13987-14002.2004","article-title":"Attenuating mutations in coxsackievirus B3 map to a conformational epitope that comprises the puff region of VP2 and the knob of VP3","volume":"78","author":"Stadnick","year":"2004","journal-title":"J. Virol."},{"key":"10.1016\/j.omton.2025.200999_bib48","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.virs.2023.08.007","article-title":"Enterovirus D68 infection upregulates SOCS3 expression to inhibit JAK-STAT3 signaling and antagonize the innate interferon response of the host","volume":"38","author":"Zhang","year":"2023","journal-title":"Virol. Sin."},{"key":"10.1016\/j.omton.2025.200999_bib49","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1009057","article-title":"Foot-and-mouth disease virus VP1 target the MAVS to inhibit type-I interferon signaling and VP1 E83K mutation results in virus attenuation","volume":"16","author":"Ekanayaka","year":"2020","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.omton.2025.200999_bib50","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1016\/j.vaccine.2009.01.008","article-title":"Attenuation of coxsackievirus B3 by VP2 mutation and its application as a vaccine against virus-induced myocarditis and pancreatitis","volume":"27","author":"Park","year":"2009","journal-title":"Vaccine"}],"container-title":["Molecular Therapy Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950329925000682?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950329925000682?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:57:26Z","timestamp":1760147846000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2950329925000682"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":50,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S2950329925000682"],"URL":"https:\/\/doi.org\/10.1016\/j.omton.2025.200999","relation":{},"ISSN":["2950-3299"],"issn-type":[{"type":"print","value":"2950-3299"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An attenuated coxsackievirus B5 mutant carrying VP1-N157K retains oncolytic potency against non-small cell lung cancer","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omton.2025.200999","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}],"article-number":"200999"}}